BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Align Tech (ALGN – Research Report). Stay Ahead of the Mar ...

In the wake of the stock market’s selloff, 125 of the 855 US-listed stocks Morningstar covers now sit at 5 stars, signaling ...

Compared to the aggregate P/E ratio of the 128.64 in the Health Care Providers & Services industry, Quest Diagnostics Inc ... In summary, while the price-to-earnings ratio is a valuable tool ...

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

This was the stock's second consecutive day of losses.

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

Quest Diagnostics price target raised to $198 from $190 at BofA BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on ...